Shortened Stelara dose interval may improve activity in Crohn’s disease

Clinical and biological indices of disease activity improved in patients with Crohn’s disease when researchers shortened the Stelara 90 mg dose from every 8 weeks to every 4 weeks.”Little is known about the effects of shortening the dosing interval for patients with Crohn’s disease who do not respond to ustekinumab at the standard dose of 90 mg every 8 weeks,” Jacob E. Ollech, MD, of the Inflammatory Bowel Disease Center at the University of Chicago Medicine, told Healio Gastroenterology and Liver Disease. “In our study, we reported that shortening the ustekinumab 90Read More

Share on facebook
Share on twitter
Share on linkedin